2 completed, 1 not yet recruiting, 1 terminated. 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Chelating Agents: new trials by email Literature Review of Chelating Agents trials Research Report on Chelating Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Chelators in Lead-Burdened Type 2 Diabetic Nephropathy chelator - Lead-Burdened Type 2 Diabetic Nephropathy | Not applicable | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 42 | 2026-08-01 | 2026-07-16 |
| Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients ICL670, Chelation, No chelation - Aplastic Anemia | Phase 4 | Terminated | Novartis Pharmaceuticals | 15 | 2014-06-23 | 2019-08-16 |
| Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Deferasirox - Myelodysplastic Syndromes, Iron Overload | Phase 4 | Completed | Novartis Pharmaceuticals | 24 | 2005-09-01 | 2021-06-24 |
| Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients Deferasirox - Myelodysplastic Syndrome, Iron Overload | Phase 2 | Completed | Novartis Pharmaceuticals | 176 | 2005-07-25 | 2021-08-16 |
Iron Overload (2) · Myelodysplastic Syndromes (2) · Anemia, Aplastic (1)
Novartis Pharmaceuticals (3) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1)
United States (2) · Canada (1) · Russia (1)